corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 13122

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Connecticut joins states suing over Zyprexa
Associated Press 2008 Mar 11
http://www.ktva.com/alaska/ci_8535276


Full text:

Connecticut is joining at least nine other states suing drug maker Eli Lilly and Co. over the antipsychotic drug Zyprexa. Attorney General Richard Blumenthal says Connecticut’s lawsuit seeks to recover more than $190 million that the state’s medical assistance program spent on Zyprexa over more than a decade.

The lawsuit accuses Indianapolis-based Eli Lilly of running an illegal marketing campaign to promote Zyprexa for unapproved off-label uses, including treating children.

Blumenthal says the campaign also concealed risks associated with the drug, including diabetes, weight gain and cardiovascular problems.

A court in Alaska is currently hearing that state’s lawsuit, and eight other states have sued as well. A spokeswoman for Eli Lilly says that the claims in the lawsuit are without merit and the company is committed to high ethical standards and to promoting medications only for approved uses.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.